Chengdu Dawei Pharmaceutical Technology

Chengdu Dawei Pharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, focused on the research and development of innovative small molecule drugs. The company primarily targets metabolic diseases, with a significant emphasis on treatments for hyperuricemia, gout, and type 2 diabetes. Its lead candidate, DWP-022, is a potent URAT1 inhibitor currently undergoing clinical evaluation for the management of chronic gout. Dawei Pharmaceutical leverages its internal R&D capabilities to advance a pipeline of candidates designed to address unmet medical needs in the metabolic and endocrine therapeutic areas. The company aims to provide high-quality, affordable innovative medicines for patients globally.